suppresses progression of renal disease. Dual blockade of the RAS with ACE inhibitors and AT1 receptor blockers may provide renal benefit beyond therapy with either drug alone, due to their potential additive beneficial effect. Tubulointerstitial (TI) fibrosis is a common feature of progressive renal injury in almost all forms of renal diseases. It has been shown that TI injury is a more consistent predictor of functional impairment than glomerular damage 1, 2) . Chronic inflammation generally precedes the development of fibrosis and inflammatory cytokines are important mediators of fibrogenesis.
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Patients with TI fibrosis have a rather poor prognosis and often progress to end-stage renal failure 3) . About De p a r t me n to fP e d i a t r i c s , C o l l e g eo fMe d i c i n e , I n j eUn i v e r s i t y , S a n g g y eP a i kHo s p i t a l ,S e o u l , Ko r e a Te l : 0 2 ) 9 5 0 -1 0 7 4 F a x: 0 2 ) 9 5 1 -1 2 4 6 E -ma i l : k o o j w9 @s a n g g y e p a i k . a c . k r to pathologic events originating in these neighboring areas. Structural derangements of the TI compartment occur in virtually all progressive renal diseases 4) .
An expansion of the cortical interstitium is highly correlated with tubular lesions, especially tubular atrophy. The widening of the interstitial space in chronic renal diseases is mainly due to increased extracellular matrix (ECM), and increased cellularity (fibroblasts, macrophages, and lymphocytes) may also contribute to the tubulointerstitial fibrosis [5] [6] [7] . However, once renal damage reaches a certain threshold, progression of renal disease is consistent, irreversible, and largely independent of the initial injury. .
Renal injury and repair comprises a delicate balance between cell loss and proliferation and ECM accumulation and remodeling 9) . In rodents complete ureteral obstruction induces aggressive interstitial fibrosis and tubular atrophy. Although technically challenging, some investigators have successfully relieved the obstruction and reported significant reduction in interstitial fibrosis severity 10) . So it is possible to investigate and clarify the mechanism of renal repair or remodeling after renal fibrosis.
Tubulointerstitial fibrosis
Tubules and interstitium make up approximately 80% of the renal volume, and occupy the compartment referred to as the tubulointerstitium. The interstitium space takes up 10% of rat and up to 17% of dog and rabbit kidneys, including 7 to 9% of renal cortex, 3 to 5% of outer medulla and 30 to 40% of inner medulla and papillary tip [10] [11] [12] [13] . It is made up of both cellular and matrix components. The matrix is made up of a fibrillar net of interstitial and basement membrane collagens and associated proteoglycans, glycoproteins and interstitial fluid. The interstitial compartment not only provides structural support for the individual nephrons, but also serves as a conduit for solute transport 12) . It is also the site of production of several hormones and cytokines such as erythropoietin and prostaglandins.
Renal fibrosis is pathologically characterized by interstitial fibrosis, tubular atrophy, capillary loss, and podocyte depletion. In most chronic kidney diseases there is an intimate relationship between interstitial fibrosis and tubular atrophy, both of which are closely correlated with the decline in renal function1 4) . Careful pathological analysis revealed that the impairment of renal function correlates better with the extent of TI damage than with the degree of glomerular damage 2) . It might be possible to assume that interstitial fibrosis causes tubular atrophy, although this is difficult to prove. The underlying cellular events leading to these histologic presentations are even more complicated; they include mesangial and fibroblast activation, tubular epithelial to mesenchymal transition (EMT), monocyte/macrophage and T-cell infiltration, and cell apoptosis 14, 15) .
In renal fibrosis, a balance between the matrix synthesis and matrix degradation is changed due to increased matrix synthesis or decreased degradation 3) .
Renal fibrogenesis may be divided into three phases:
induction, matrix synthesis, and resolution 6) . The in- and tubular atrophy appears to be irreversible 3, 16) .
After the initial injury, the affected kidney tissues undergo a series of events in an attempt to repair and recover from the damage. These processes include kidney resident cell activation, which leads to the production and secretion of proinflammatory cytokines. .
TI injury is mediated by massive proteinuria containing a large amount of complement components and chronic hypoxia with loss of peritubular capillaries in the tubulointerstitium 17) . Proteinuria may contribute to tubulointerstitial damage by activation of nuclear factor-kappa B (NF-κB) and upregulation of various proinflammatory and profibrotic genes. Inhibition of NF-κB improved TI injury and is also associated with the transdifferentiation of tubular cells into myofibroblasts 17) . Hypoxia can activate fibroblasts, change ECM metabolism of resident renal cells, and lead to eventual fibrogenesis 17) .
Unilateral ureteral obstruction study for renal interstitial fibrosis
In the study of human diabetic glomerular disease by
Fioretto et al 18) , once diabetes was cured by successful pancreas transplantation, it took 10 years for the expanded mesangial matrix to regress.
However, diabetic renal changes in man are very slow to develop and to reverse and possible manipulations of this human model are limited by ethical constraints. Therefore, unilateral ureteral obstruction (UUO) model in the rat can be used for the exploration of these phenomena rapidly. UUO represents a well-established experimental model of progressive interstitial expansion and fibrosis 19, 20) . UUO causes rapid interstitial expansion and fibrosis and tubular injury 19, 20) . In the rabbit, interstitial fibrosis is seen in the affected kidney at 7 days (D) of UUO. Moreover, increased synthesis of ECM components [collagens I, III, and IV, fibronectin and heparan sulfate proteoglycan] is detectable at 3-7D of UUO 19) . The expression of transforming growth factor (TGF)-β in rat kidneys after 1 and 7D of UUO is also increased in the interstitium and in perivascular areas 20) . These alterations are remarkably alleviated by prior or concomitant use of an angiotensin converting enzyme (ACE) inhibitor and a specific angiotensin II receptor blocker [19] [20] [21] . These data suggest that interstitial fibro- . Thus, this cytokine likely contributes importantly to the accumulation of ECM protein in the renal interstitium.
Several cytokines might initiate fibrogenesis, but TGF-β1 is considered a major stimulating factor.
In the animal experiment 10) . This partial reversal was accom- . ACE inhibitor may accelerate healing process through yet to be described mechanisms but probably not through anti-inflammatory effects. . Clinical trials suggest that AT1RAs reduce microalbuminuria and proteinuria and retard the progression of diabetic and nondiabetic kidney disease, which is similar to ACE inhibitors 31, 32) .
Renoprotective benefits of renin angiotensin system inhibition
AT II, the main peptide of the RAS, is involved in the pathogenesis of renal diseases 27) . This peptide acts through its binding to two specific receptors, angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors 33) . In adult tissues, the AT1 receptor is distributed in the vasculature, kidney, adrenal gland, heart, liver, and brain 34) . In healthy adults, the AT2 receptor is present only in the adrenal medulla, uterus, ovary, vascular endothelium, and distinct brain areas 34) .
The AT2 receptor is also widely distributed in the fetus. , and improve selectivity of proteinuria in patients with glomerular diseases 39, 40) . Large scale clinical trials confirmed the benefits of ACE inhibitors against a variety of renal diseases with their antiproteinuric effects 41, 42) . Furthermore, recent studies demonstrated that the greater beneficial effect of ACE inhibitors in renal disease patients with higher baseline proteinuria could be explained by the greater antiproteinuric effects in these patients 43) . Thus, one of the protective mechanisms of ACE inhibitors and
AT1RAs is the reduction of the amount of proteinuria. .
Theoretically dual blockade of the RAS with ACE inhibitor and AT1RAs may provide renal benefit beyond therapy with either drug alone.
Clinical studies with ACE inhibitor and AT1RA
showed that BP and proteinuria were reduced without hyperkalemia. Because these studies demonstrate a reduction in BP with combination therapy, it is not possible to attribute the reduction in proteinuria to dual blockade alone. In patients with IgA nephropathy, the combination of losartan and enalapril decreased urinary protein excretion, whereas doubling the dose of either medication had no further effect on proteinuria 45) . The combination therapy in patients with nondiabetic kidney disease reduced proteinuria by 59% as compared with 45% in those treated with the AT1RA alone 46) .
However, Agarwal et al 47) showed that combination therapy was not superior to maximal-dose ACE inhibitor therapy in decreasing proteinuria in patients with renal disease. This raises the question of whether combination therapy is superior to maximal dose monotherapy 48) . Although most studies suggest that dual blockade has renal benefit, maximal ACE inhibition has not been used in all studies 47, 48) . These studies also have several limitations to draw firm conclusion about combination therapy in renal disease, such as small sample size, use of surrogate markers of renal protection, and short-term follow-up. Some authors suggested following recommendation; 1) titration of the single agent to maximal dose to control BP and proteinuria, 2) if proteinuria remains greater than 1 g/d, add a second agent to block the RAS further 48) .
Animal experiment with UUO showed slightly disappointing outcome after relief of UUO 49) . With ACE inhibitor (enalapril) or AT1RA (losartan) the decrease in the interstitial expansion was nearly 30%, significantly faster than with release alone (14% reduction). Unfortunately, complete recovery of interstitial damage developed after UUO could not be reached even after the treatment of ACE inhibitor plus However, these treatments did not cause regression of renal damage, suggesting that novel approaches are needed.
A recent experiment showed that CTGF might be included as a potential interesting candidate for antifibrotic treatments 33) . TGF-β is an important regula- 
